MIME-Version: 1.0
Content-Location: file:///C:/0669C639/26Feb2009.htm
Content-Transfer-Encoding: quoted-printable
Content-Type: text/html; charset="us-ascii"

<html xmlns:o=3D"urn:schemas-microsoft-com:office:office"
xmlns:w=3D"urn:schemas-microsoft-com:office:word"
xmlns:st1=3D"urn:schemas-microsoft-com:office:smarttags"
xmlns=3D"http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=3DContent-Type content=3D"text/html; charset=3Dus-ascii">
<meta name=3DProgId content=3DWord.Document>
<meta name=3DGenerator content=3D"Microsoft Word 11">
<meta name=3DOriginator content=3D"Microsoft Word 11">
<link rel=3DFile-List href=3D"26Feb2009_files/filelist.xml">
<title>26 Feb 2009</title>
<o:SmartTagType namespaceuri=3D"urn:schemas-microsoft-com:office:smarttags"
 name=3D"State"/>
<o:SmartTagType namespaceuri=3D"urn:schemas-microsoft-com:office:smarttags"
 name=3D"City"/>
<o:SmartTagType namespaceuri=3D"urn:schemas-microsoft-com:office:smarttags"
 name=3D"PlaceType"/>
<o:SmartTagType namespaceuri=3D"urn:schemas-microsoft-com:office:smarttags"
 name=3D"PlaceName"/>
<o:SmartTagType namespaceuri=3D"urn:schemas-microsoft-com:office:smarttags"
 name=3D"place"/>
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>BARBARA</o:Author>
  <o:LastAuthor>BARBARA</o:LastAuthor>
  <o:Revision>1</o:Revision>
  <o:TotalTime>1</o:TotalTime>
  <o:Created>2009-02-27T00:08:00Z</o:Created>
  <o:LastSaved>2009-02-27T00:09:00Z</o:LastSaved>
  <o:Pages>1</o:Pages>
  <o:Words>347</o:Words>
  <o:Characters>1982</o:Characters>
  <o:Lines>16</o:Lines>
  <o:Paragraphs>4</o:Paragraphs>
  <o:CharactersWithSpaces>2325</o:CharactersWithSpaces>
  <o:Version>11.9999</o:Version>
 </o:DocumentProperties>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:SpellingState>Clean</w:SpellingState>
  <w:GrammarState>Clean</w:GrammarState>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
  </w:Compatibility>
  <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>
 </w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:LatentStyles DefLockedState=3D"false" LatentStyleCount=3D"156">
 </w:LatentStyles>
</xml><![endif]--><!--[if !mso]><object
 classid=3D"clsid:38481807-CA0E-42D2-BF39-B33AF135CC4D" id=3Dieooui></objec=
t>
<style>
st1\:*{behavior:url(#ieooui) }
</style>
<![endif]-->
<style>
<!--
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	margin:0in;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
a:link, span.MsoHyperlink
	{color:#0000CC;
	text-decoration:underline;
	text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;
	text-underline:single;}
span.SpellE
	{mso-style-name:"";
	mso-spl-e:yes;}
span.GramE
	{mso-style-name:"";
	mso-gram-e:yes;}
@page Section1
	{size:8.5in 11.0in;
	margin:1.0in 1.25in 1.0in 1.25in;
	mso-header-margin:.5in;
	mso-footer-margin:.5in;
	mso-paper-source:0;}
div.Section1
	{page:Section1;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Table Normal";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-parent:"";
	mso-padding-alt:0in 5.4pt 0in 5.4pt;
	mso-para-margin:0in;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-ansi-language:#0400;
	mso-fareast-language:#0400;
	mso-bidi-language:#0400;}
</style>
<![endif]-->
</head>

<body lang=3DEN-US link=3D"#0000CC" vlink=3Dpurple style=3D'tab-interval:.5=
in'>

<div class=3DSection1>

<p class=3DMsoNormal><span style=3D'font-size:9.0pt;mso-bidi-font-size:7.5p=
t;
font-family:Arial'>26 Feb 2009<br>
<br>
</span><b style=3D'mso-bidi-font-weight:normal'><span style=3D'mso-bidi-fon=
t-size:
7.5pt;font-family:Arial'>WHO Announces Agreement on Live, Attenuated Influe=
nza
Vaccines</span></b><span style=3D'font-size:9.0pt;mso-bidi-font-size:7.5pt;
font-family:Arial'><br>
<br>
<br>
<span class=3DGramE>On</span> February 25 the World Health Organization (WH=
O)
posted on the top of their website homepage a synopsis of &quot;Progress in
Pandemic Influenza Vaccine Preparedness&quot;. They noted that by early Apr=
il
(within 6 weeks from now<span class=3DGramE>) &nbsp;revised</span> and upda=
ted
(from 2005) guidelines will be issued by WHO on their entire global influen=
za
preparedness plan.<br>
<br>
In a major announcement the WHO reported that it has recently signed an
agreement with the vaccines division (called &quot;<span class=3DSpellE>Nob=
ilon</span>&quot;)of
the company Schering-Plough &nbsp;&quot;in which WHO has been granted a
non-exclusive license to develop, register, manufacture, use and sell seaso=
nal
and pandemic live, <span class=3DSpellE>attenutated</span> (or weakened)
influenza (LAIV) vaccines produced on chicken eggs. WHO will thus be able to
grant sub-licenses to vaccine manufacturers in developing countries who are
working within the framework of the WHO Global Influenza Action Plan to
Increase Vaccine Supply&quot;<span class=3DGramE>.</span><br>
<br>
The WHO emphasized that the above nations will then be able to provide such
vaccines royalty-free to their public sectors.<br>
<br>
Live attenuated influenza vaccines were noted by WHO to have the following
three advantages over the current inactivated flu vaccines<span class=3DGra=
mE>:</span><br>
<br>
1. &quot;The number of doses of LAIV which can be produced per egg are much
higher than with inactivated vaccines, Especially in a pandemic situation, =
this
is considered to be a major advantage since more vaccine doses can be made
available in a shorter time.<br>
<br>
<span class=3DGramE>2.LAIVs</span> are administered in the nose through a v=
ery
simple device, which can be much easier to put into practice on a large-sca=
le
by non-medically trained staff in case of a pandemic.<br>
<br>
3. Since a LAIV mimics natural infection more than <span class=3DSpellE>inj=
ectable</span>
vaccines, it is expected that LAIV induces a more rapid and broader immune
response. This may be of particular interest in pandemic situations.&quot;<=
br>
<span style=3D'color:#550055'><br>
&gt; &gt;<br>
&gt; &gt; Daniel R. <span class=3DSpellE>Lucey</span>, MD, MPH<br>
&gt; &gt; <span class=3DSpellE>EROne</span> Institute, Department of Emerge=
ncy
Medicine<br>
&gt; &gt; <st1:PlaceName w:st=3D"on">Washington</st1:PlaceName> <st1:PlaceT=
ype
w:st=3D"on">Hospital</st1:PlaceType> <st1:PlaceType w:st=3D"on">Center</st1=
:PlaceType><br>
&gt; &gt; Adjunct Professor <span class=3DSpellE><span class=3DGramE>fo</sp=
an></span>
Microbiology and Immunology<br>
&gt; &gt; <st1:place w:st=3D"on"><st1:City w:st=3D"on">Georgetown University
  Medical Center</st1:City>, <st1:State w:st=3D"on">Washington</st1:State><=
/st1:place>,
DC<br>
</span>&gt; &gt; Website for this posting (requires Internet Explorer):<a
href=3D"http://www.BePast.org" target=3D"_blank">www.BePast.org</a>&lt;<a
href=3D"http://www.bepast.org/" target=3D"_blank">http:<wbr>//www.bepast.or=
g/</a>&gt;<br>
&gt; &gt;<br>
&gt; &gt;</span><span style=3D'font-size:9.0pt;mso-bidi-font-size:12.0pt'><=
o:p></o:p></span></p>

</div>

</body>

</html>
